Uterine effects of tamoxifen: A prospective study

International Journal of Gynecological Cancer

Volumn 16, Issue 2, 2006, Pages 814-820

  McGonigle, K F ^a   Smith, D D ^b   Marx, H F ^b   Morgan, R J ^b   Vasilev, S A ^c   Roy, S ^d   Wong, P T ^b   Simpson, J F ^e   Wilczynski, S P ^b  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c Gynecologic Oncology   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e VANDERBILT UNIVERSITY   (United States)

Author keywords

Endometrial cancer; Endometrial polyps; Tamoxifen; Transvaginal ultrasound; vaginal maturation indexes

Indexed keywords

FOLLITROPIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; DRUG EFFECT; ENDOMETRIUM ATROPHY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; ESTROGEN ACTIVITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE; TRANSVAGINAL ECHOGRAPHY; VAGINA; VAGINA BLEEDING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; TAMOXIFEN; UTERUS;

EID: 33646027309     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00525.x     Document Type: Article

References (44)

1. Althuis MD Sexton M Langenberg P et al Surveillance for uterine abnormalities in tamoxifen-treated breast carcinoma survivors. A community-based study Cancer 2000 89 800 10
2. Cohen I Rosen DJ Shapira J et al Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic postmenopausal breast cancer patients Gynecol Oncol 1994 52 185 90
3. Decensi A Fontana V Bruno S Gustavino C Gatteschi B Costa A Effect of tamoxifen on endometrial proliferation J Clin Oncol 1996 14 434 40
4. Deligdisch L Kalir T Cohen CJ Latour M Bouedec G Penault-Llorca F Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer Gynecol Oncol 2000 78 181 6
5. Franchi M Ghezzi F Donadello N Zanaboni F Bertetta P Bolis P Endometrial thickness in tamoxifen-treated patients: an independent predictor of endometrial disease Obstet Gynecol 1999 93 1004 8
6. Lahti E Blanco G Kauppila A Apaja-Sarkkinen M Taskinen PJ Laatikainen T Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen Obstet Gynecol 1993 81 660 4
7. Mourits MJE DeVries EGE Willemse PHB TenHoor KA Hollema H VanderZee AGJ Tamoxifen treatment and gynecologic side effects: a review Obstet Gynecol 2001 97 855 66
8. Schwartz LB Rutkowski N Horan C Nachtigall LE Snyder J Goldstein ST Use of transvaginal ultrasonography to monitor the effects of tamoxifen on uterine leiomyoma size and ovarian cyst formation J Ultrasound Med 1998 17 699 703
9. Vosse M Renard F Coibion M Neven P Nogaret JM Hertens D Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring Eur J Obstet Gynecol 2002 101 58 63
10. American College of Obstetricians and Gynecologists Tamoxifen and endometrial cancer. Committee Opinion No.:169 Washington, DC American College of Obstetricians and Gynecologists 1996
11. Cohen I Bernheim J Azaria R Tepper R Sharony R Beyth Y Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients Gynecol Oncol 1999 75 136 41
12. Fisher B Costantino JP Redmond CK et al Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J Natl Cancer Inst 1994 86 527 37
13. Katase K Sugiyama Y Hasumi K Yoshiomoto M Kasumi F The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma Cancer 1998 82 1698 703
14. Kloos I Delaloge S Pautier P et al Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature Int J Gynecol Cancer 2002 12 496 500
15. McCluggage WG Bryson C Lamki H Boyle DD Benign, borderline, and malignant endometrioid neoplasia arising in endometriosis in association with tamoxifen therapy Int J Gynecol Pathol 2000 19 276 9
16. Ramondetta LM Sherwood JB Dunton CJ et al Endometrial cancer in polyps associated with tamoxifen use Am J Obstet Gynecol 1999 180 340 1
17. Silva EG Tornos C Malpica A Mitchell MF Uterine neoplasms in patients treated with tamoxifen J Cell Biochem 1995 23 179 83
18. Chetkowski RJ Meldrum DR Steingold KA et al Biologic effects of transdermal estradiol N Engl J Med 1986 314 1615 20
19. Kobilkova J Cytologic study of the level of estrogen during the reproductive age Acta Cytol 1967 11 497 500
20. Mortimer JE Boucher L Baty J et al Effect of tamoxifen on sexual functioning in patients with breast cancer J Clin Oncol 1999 17 1488 92
21. Vardy MD Lindsay R Scotti RY et al Short-term urogenital effects of raloxifene, tamoxifen, and estrogen Am J Obstet Gynecol 2003 189 81 8
22. Neven P Vernaeve H Guidelines for monitoring patients taking tamoxifen treatment Drug Saf 2000 22 1 11
23. Tregon ML Blumel JE Tarin JJ Cano A The early response of the postmenopausal endometrium to tamoxifen: expression of estrogen receptors, progesterone receptors, and Ki-67-antigen Menopause 2003 10 154 9
24. Cohen I Endometrial pathologies associated with postmenopausal tamoxifen treatment: review Gynecol Oncol 2004 94 256 66
25. Woodruff JD Pickar JH for the Menopause Study Group Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogen (Premarin) with medroxypreogesterone acetate or conjugated estrogens alone Am J Obstet Gynecol 1994 170 1213 23
26. Achiron R Lipitz S Sivan E Goldenberg M Mashiach S Sonohysterography for ultrasonographic evaluation of tamoxifen-associated cystic thickened endometrium J Ultrasound Med 1995 14 685 8
27. Ascher SM Imaoka I Lage JM Tamoxifen-induced uterine abnormalities: the role of imaging Radiology 2000 214 29 38
28. Bese T Kosebay D Demirkiran F Arvas M Bese N Mandel N Ultrasonographic appearance of endometrium in postmenopausal breast cancer patients receiving tamoxifen Eur J Obstet Gynecol Reprod Biol 1996 67 157 62
29. Dijkhuizen FP Brolmann HA Potters AE Conbres MY Heintz AP The accuracy of transvaginal ultrasonography in the diagnosis of endometrial abnormalities Obstet Gynecol 1996 87 345 9
30. Fong K Causer P Atri M Lytwyn A Kung R Transvaginal US and hysterosonography in postmenopausal women with breast cancer receiving tamoxifen: correlation with hysteroscopy and pathologic study Radiographics 2003 23 137 55
31. Giorgio G Crivellari D Veronesi A et al Comparison of ultrasonography, hysteroscopy, and biopsy in the diagnosis of endometrial lesions in postmenopausal tamoxifen-treated patients Acta Obstet Gynecol Scand 2002 81 975 80
32. Goldstein SR Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen Am J Obstet Gynecol 1994 170 447 51
33. McGonigle KF Shaw SL Vasilev SA Odom-Maryon T Roy S Simpson JF Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy Am J Obstet Gynecol 1998 178 1145 50
34. Ciatto S Cecchini S Gervasi G Landidi A Zappa M Crocetti E Surveillance for endometrial cancer with transvaginal ultrasonography of breast cancer patients under tamoxifen treatment Br J Cancer 2003 88 1175 9
35. Cheng W-F Lin H-H Torng P-L et al Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients Gynecol Oncol 1997 66 233 7
36. Cook LS Weiss NS Schwartz SM et al Population-based study of tamoxifen therapy and subsequent ovarian, endometrial and breast cancers J Natl Cancer Inst 1995 87 1359 64
37. Bergman L Beelen MLR Gallee MPW et al Risk and prognosis of endometrial cancer after tamoxifen for breast cancer Lancet 2000 356 881 7
38. Bernstein L Deapen D Cerhan JR et al Tamoxifen therapy for breast cancer and endometrial cancer risk J Natl Cancer Inst 1999 91 1654 62
39. Gardner FJE Konje JC Abrams KR et al Endometrial protection from tamoxifen-stimulated changes by levonorgestrel-related intrauterine system: a randomised controlled trial Lancet 2000 356 1711 7
40. SWOG S9630-Phase III Intergroup: a randomized comparison of medroxyprogesterone acetate (MPA) and observation for prevention of endometrial pathology in postmenopausal breast cancer patients treated with tamoxifen
41. Winer EP Hudis C Burstein HJ et al American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002 J Clin Oncol 2002 20 3317 27
42. Winer EP Hudis C Burstein HJ et al American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting J Clin Oncol 2003 21 2597 9
43. Coombes RC Hall E Gibson LJ et al A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 2004 350 1081 92
44. Goss PE Ingle JN Martino S et al A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast Cancer N Engl J Med 2003 349 1793 802